EU nod for Sanofi’s next-gen rabies vaccine for all age groups
By: IPP Bureau
Last updated : November 22, 2026 8:46 am
VaxRabeo has been formulated to minimise the risk of allergic reactions
Sanofi’s next-generation rabies vaccine, VaxRabeo, has received its first marketing authorisation after the European Commission approved it for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) against rabies across all age groups.
The approval marks a significant milestone for Sanofi and follows a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use on September 17, 2026.
Manufactured using advanced Vero-cell technology, VaxRabeo has been formulated to minimise the risk of allergic reactions. It also offers a longer shelf life and improved thermostability compared with Sanofi’s existing rabies vaccines.
The approval comes against the backdrop of a persistent global public health threat. Rabies remains present in 150 countries and claims approximately 59,000 lives every year, according to World Health Organization (WHO) estimates.
Despite being entirely vaccine-preventable, rabies is almost always fatal once clinical symptoms emerge. The virus is transmitted primarily through the saliva of infected animals, with dog bites accounting for most cases. No effective treatment exists once the disease becomes symptomatic, making timely vaccination critical to survival.
An estimated 29 million people worldwide receive post-exposure vaccination against rabies every year, according to the WHO. PEP involves vaccination, often in combination with rabies immunoglobulins, to prevent the disease from developing following exposure.
"Death from rabies should be prevented at all costs; it is entirely preventable with vaccination provided on time. This first approval of VaxRabeo is a proud milestone for Sanofi and reflects our commitment to rabies protection, built on five decades of expertise and innovation. With VaxRabeo, we are bringing a next-generation rabies vaccine to healthcare systems and patients," said Thomas Triomphe, Head of Vaccines, Sanofi.
The European Commission's decision is backed by a comprehensive clinical development programme that evaluated VaxRabeo against Sanofi’s existing standard-of-care rabies vaccines, Verorab and Imovax Rabies.
The studies covered both pre-exposure and post-exposure settings, included all age groups and assessed WHO-recommended vaccination schedules.
Clinical findings demonstrated that VaxRabeo generated protective antibody levels comparable to existing vaccines in PrEP, while showing a similar immunogenicity profile in PEP. The vaccine also demonstrated strong immune-boosting potential following booster doses administered 12 months or 24–36 months after initial PrEP.
Its safety profile was consistent with that of existing rabies vaccines, with no significant safety concerns identified.
The European approval represents an important addition to the global rabies prevention landscape, as health systems continue to confront a disease that remains almost universally fatal after symptoms appear but is preventable through timely vaccination.